Article
Sorafenib inhibits ovarian inflammation and fibrosis in polycystic ovary syndrome by targeting the PDGFA/PDGFRα/NF-κB pathway in granulosa cells
2 May 2025
Abstract excerpt
The etiology of polycystic ovary syndrome (PCOS) remains unknown. However, emerging evidence is increasingly suggesting that ovarian inflammation and fibrosis are among the primary causes of pathological changes. Sorafenib is a multiple kinases inhibitor that targets receptor tyrosine kinases including vascular endothelial growth factor receptor and platelet-derived growth factor receptor. Sorafenib was found to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
